Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Pre-Mkt 08-03 05:18:03 EDT

18.25

-1.14

-5.88%

High19.73	Low18.24	Vol923.87K
Open19.50	D1 Closing19.39	Amplitude7.68%
Mkt Cap965.48M	Tradable Cap741.87M	Total Shares52.90M
T/O17.22M	T/O Rate2.27%	Tradable Shares40.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":18.25,"timestamp":1785528000000,"preClose":19.39,"halted":0,"volume":923867,"delay":0,"changeRate":-0.05879319236719961,"floatShares":40650400,"shares":52902989,"eps":-5.57,"marketStatus":"Pre-Mkt","change":-1.14,"latestTime":"08-03 05:18:03 EDT","open":19.5,"high":19.73,"low":18.24,"amount":17219067.329079002,"amplitude":0.076844,"askPrice":20.13,"askSize":100,"bidPrice":18,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.57,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785763800000},"marketStatusCode":1,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":18.25,"postHourTrading":{"tag":"盘后","latestPrice":18.4,"preClose":18.25,"latestTime":"19:46 EDT","volume":31103,"amount":576792.5472,"timestamp":1785541561127,"change":0.15,"changeRate":0.008219,"amplitude":0.056438},"volumeRatio":1.0243274683034398,"impliedVol":0.7868,"impliedVolPercentile":0.3},"requestUrl":"/m/hq/s/AVTX/tweets","defaultTab":"tweets","newsList":[{"id":"2655816802","title":"Avalo Therapeutics CMO Mittie Doyle Disposes of Common Shares Worth $20,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816802","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816802?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:06","pubTimestamp":1785355610,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CMO Mittie Doyle disposes of common shares worth $20,000Avalo Therapeutics Chief Medical Officer Doyle Mittie exercised stock options for 1,000 shares at USD 12.65 on July 27, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL8yFfN3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle Disposes of Common Shares Worth $20,000","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655400838","title":"Avalo Therapeutics - Selling Stockholders May Sell up to 128,189 Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2655400838","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655400838?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:44","pubTimestamp":1785271465,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1FI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652800552","title":"Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2652800552","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652800552?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:22","pubTimestamp":1784319732,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) on Friday filed a registration statement with the US Securities and Exchange Commission saying that some shareholders may from time to time sell up to 128,189 of its shares.The company said it will not receive any proceeds from the proposed sale.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","LENZ","AVTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652572238","title":"Avalo Therapeutics files to sell 128,189 shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2652572238","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652572238?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:05","pubTimestamp":1784318711,"startTime":"0","endTime":"0","summary":"16:04 EDT Avalo Therapeutics (AVTX) files to sell 128,189 shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-files-to-sell-128189-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-files-to-sell-128189-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVTX","LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649300959","title":"What Avalo Therapeutics (AVTX)'s Russell Index Additions and Board Refresh Mean for Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2649300959","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649300959?lang=en_us&edition=fundamental","pubTime":"2026-07-08 03:48","pubTimestamp":1783453685,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics was recently added to multiple Russell indices and appointed veteran biopharma executive Ron Philip to its board, moves that follow positive Phase 2 data for its lead IL‑1β antibody abdakibart in hidradenitis suppurativa and preparation for investor meetings at the Leerink Partners Therapeutics Forum.\nTogether, the index inclusions, strengthened governance, and focus on IL‑1β‑targeted therapies highlight how a once‑smaller biotech is gaining broader institutional...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/what-avalo-therapeutics-avtxs-russell-index-additions-and-bo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/what-avalo-therapeutics-avtxs-russell-index-additions-and-bo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624485","title":"U.S. Stocks on the Move-core Natural Resources, Grabagun, Terawulf","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624485?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:09","pubTimestamp":1783343380,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Core Natural Resources, GrabAGun, TeraWulfWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL6N4380KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","IE00BN0W2V16.EUR","PSCM","CLVT","LU2506952170.USD","BK4139","BK4561","GD","LU2506951958.HKD","LU0994945656.USD","BK4588","SEI","CNR","LU0757428866.USD","FOWF","WULF","BK4595","LU0426412945.USD","LU1043141396.HKD","BK4023","BK4560","BK4539","BK4123","BK4585","BK4200","FDIG","LU0950375773.USD","XES","IE00BN0W2T93.GBP","CHKP","COAL","LU0170899867.USD","LU0426417589.USD","SOLS","PPA","LU0823417653.USD","S","SHLD","BK4600","LU1043141123.HKD","IE0031619046.USD","LU2506952097.USD","PEW","LU0823417737.USD","SG9999015978.USD","BK4179","ESI","AVTX","OIH","WULX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624621","title":"Leerink Starts Avalo at \"outperform\" on Skin Disease Drug Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624621?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:19","pubTimestamp":1783340391,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink starts Avalo at \"outperform\" on skin disease drug potential** Shares of drug developer Avalo TherapeuticsAVTX.Orise 2.9% to $19.40 premarket** Leerink Partners initiates coverage of AVTX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL4N4380QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","IE00BGHQF631.EUR","LU0689472784.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","IE00BDGV0183.EUR","LU0098860793.USD","LU0882574055.USD","IYH","AGNG","XLV","VHT","JDOC","BK4139","BK4588","LU0234570918.USD","LU0256863811.USD","LU2089984988.USD","LU2129689605.HKD","LU0114720955.EUR","ABBV","LU0058720904.USD","LU2087621335.USD","FTXH","LU0203347892.USD","LU0310800379.SGD","LU2129689514.USD","LU2347655156.SGD","FHLC","LU0289739343.SGD","LU0511384066.AUD","PPH","AVTX","LU1267930573.SGD","IE00B3PB1722.GBP","IE00BSNM7G36.USD","LU1057294990.SGD","SG9999001440.SGD","IE000WAW04H5.SGD","LU0124676726.USD","LU1934455277.USD","LU2237443978.SGD","LU2089284900.SGD","LU1670627923.USD","MEDX","PJP","RXL","LU0211327993.USD","IXJ","LU0211328371.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649366625","title":"Avalo Therapeutics Inc : Leerink Partners Initiates Coverage with Outperform Rating; Target Price $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2649366625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649366625?lang=en_us&edition=fundamental","pubTime":"2026-07-06 18:52","pubTimestamp":1783335176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648384906","title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 4,654 Common Shares Valued at $93,080","url":"https://stock-news.laohu8.com/highlight/detail?id=2648384906","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648384906?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:07","pubTimestamp":1783022820,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CMO Mittie Doyle disposes of 4,654 common shares valued at $93,080Avalo Therapeutics Chief Medical Officer Doyle Mittie reported option exercises on June 30, 2026, acquiring 4,654 c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL2ZkMFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 4,654 Common Shares Valued at $93,080","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646351820","title":"Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2646351820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646351820?lang=en_us&edition=fundamental","pubTime":"2026-06-26 19:00","pubTimestamp":1782471612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42X0Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646485389","title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 1,450 Common Shares Valued at $26,100","url":"https://stock-news.laohu8.com/highlight/detail?id=2646485389","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646485389?lang=en_us&edition=fundamental","pubTime":"2026-06-26 05:26","pubTimestamp":1782422760,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CMO Mittie Doyle disposes of 1,450 common shares valued at $26,100Avalo Therapeutics Chief Medical Officer Mittie Doyle sold 1,450 common shares on June 23 at $18.The sale followed ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL1kN0z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 1,450 Common Shares Valued at $26,100","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646389118","title":"Avalo Therapeutics Director Philip Ron M Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2646389118","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646389118?lang=en_us&edition=fundamental","pubTime":"2026-06-26 05:24","pubTimestamp":1782422662,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics director Philip Ron M files initial beneficial ownership statementAvalo Therapeutics filed a Form 3 disclosing Philip Ron M as a director in an initial statement of beneficial owner","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL7B5Lbs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645838439","title":"Avalo Therapeutics appoints Ron Philip to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645838439","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645838439?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:00","pubTimestamp":1782212425,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics appointed biopharma executive Ron Philip to its board of directors.Philip is executive chair of CREATE Medicines; previously led Orbital Therapeutics through its USD 1.5 billion sale to Bristol Myers Squibb.He also ran Spark Therapeutics, including the LUXTURNA launch; supported Spark’s USD 4.8 billion sale to Roche.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL9fk3Dx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU1718418525.SGD","AVTX","BK4112","SG9999014005.SGD","IE00BJJMRZ35.SGD","LU2133065610.SGD","LU1074936037.SGD","NDAQ","LU1868836757.USD","LU2125154935.USD","LU0321505868.SGD","LU2360032135.SGD","LU1670711123.USD","LU0306806265.USD","LU1868836591.USD","LU2210150020.SGD","LU0237698245.USD","IE00B3QW5Z07.USD","LU0306807586.USD","BK4581","LU2095319765.USD","LU2242646821.SGD","IE0002141913.USD","LU1883839398.USD","LU0432979614.USD","LU0225771236.USD","SG9999014021.USD","BK4585","BK4007","IE0009355771.USD","LU1670710588.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4559","LU2242652126.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2W23.USD","BK4534","LU0985481810.HKD","LU1323610961.USD","LU2125154778.USD","BK4532","IE00BGHQF748.EUR","LU1868837300.USD","LU1868836914.USD","BMY","LU0225284248.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645916838","title":"Avalo Therapeutics Appoints Ron Philip to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645916838","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645916838?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:00","pubTimestamp":1782212400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA1P1TJ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643575153","title":"Avalo Therapeutics posts corporate deck highlighting IL-1β pipeline in hidradenitis suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643575153?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:17","pubTimestamp":1781608644,"startTime":"0","endTime":"0","summary":"Avalo outlined an IL-1β pipeline led by abdakibart  for moderate-to-severe hidradenitis suppurativa, citing positive Phase 2 topline data.LOTUS Phase 2 met its primary endpoint at week 16; combined HiSCR75 was 42.5% versus 25.6% for placebo .Combined HiSCR50 was 61.7% versus 40.7% for placebo ; dosing evaluated included 150 mg Q2W or 300 mg Q4W.Presentation cited about 500 patients studied across Phase 1 and 2; no adverse events related to neutropenia, serious infections, or opportunistic infections.AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, is expected to advance to IND in 1H 2027; cash runway projected into 2029 following USD 431.3 million financing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL8ljfKl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759760","title":"Avalo Therapeutics - to Submit Ind Application for Avtx-10 in First Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759760?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:05","pubTimestamp":1781607915,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O0AC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643597697","title":"Avalo Therapeutics Expands Pipeline With Avtx-010, a Long-Acting Next-Generation Anti-Il-1Β Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2643597697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643597697?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:05","pubTimestamp":1781607915,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O0AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643592547","title":"Avalo Therapeutics targets 1H 2027 IND for long-acting anti-IL-1β antibody AVTX-010","url":"https://stock-news.laohu8.com/highlight/detail?id=2643592547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643592547?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:04","pubTimestamp":1781607843,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics advanced AVTX-010, a long-acting next-generation anti-IL-1β antibody, to expand its inflammatory disease pipeline.IND filing planned for the first half of 2027; first-in-human studies expected to follow.No AVTX-010 clinical results were presented; the update focused on development timing.Strategy targets less frequent dosing to support adherence in chronic disease, with initial focus on hidradenitis suppurativa.Moves alongside recently reported positive Phase 2 topline results for lead drug abdakibart in hidradenitis suppurativa.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLrtFRs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU0314104364.USD","LU2210150020.SGD","AVTX","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","BK4585","LU2095319765.USD","SG9999014005.SGD","SG9999014039.USD","NDAQ","BK4588","IE00BN0W2T93.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","IE00BGHQF748.EUR","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643211773","title":"Kratos, AMD, CCEP, Avalo, WSM Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2643211773","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643211773?lang=en_us&edition=fundamental","pubTime":"2026-06-13 17:02","pubTimestamp":1781341327,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($KTOS) ), ( ($AMD) ), ( ($CCEP) ), ( ($AVTX) ) and ( ($WSM) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/kratos-amd-ccep-avalo-wsm-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/kratos-amd-ccep-avalo-wsm-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CCEP","AMD","LU2089985449.USD","LU2092937221.SGD","IE00BQXX3F31.USD","LU0198837287.USD","LU2298321311.HKD","LU2355687059.USD","LU2264538146.SGD","BK4543","AMDS","LU2237957811.SGD","BK4178","LU0174119429.USD","IE00BMPRXQ63.HKD","LU1242518931.SGD","LU2931357623.SGD","BK4575","LU0048578792.EUR","LU0127658192.USD","LU2458330243.SGD","LU1316542783.SGD","LU2242649171.HKD","LU1988902786.USD","LU0889565833.HKD","LU1951198990.SGD","LU1803068979.SGD","SG9999011175.SGD","BK4573","IE00BQXX3D17.EUR","LU1064131342.USD","LU0823434740.USD","LU2098885051.SGD","AMUU","LU0390134368.USD","LU1923623000.USD","IE00BMPRXR70.SGD","IE00BMPRXN33.USD","BK4566","LU1989764664.SGD","BK4614","SG9999001424.SGD","BK4141","LU2360108059.USD","IE00B5949003.HKD","LU2462591350.SGD","AMDD","BK4529","LU0823434583.USD","KTUP","BK4532","LU0997586606.USD","LU1303367103.USD","LU1861559042.SGD","WSM","LU1880398554.USD","AMDY","LU2250418816.HKD","SG9999003800.SGD","LU0786609619.USD","LU0056508442.USD","LU0081259029.USD","LU1880398471.USD","LU2860962120.EUR","AMDG","IE0004445239.USD","AVTX","LU0082616367.USD","AMDW","IE0009356076.USD","BK4612","BK4585","BK4512","LU0868494617.USD","LU1951200564.SGD","LU2360106780.USD","AMYY","LU0251132253.USD","BK4603","LU0942090050.USD","LU1119994140.HKD","BK4554","LU1861558580.USD","LU0048584097.USD","LU0823421416.USD","LU0109392836.USD","LU0719512351.SGD","LU0868494708.USD","LU0997587240.USD","BK4588","LU0170899867.USD","BK4177","BK4187","KTOS","LU0823421333.USD","LU1852331112.SGD","BK4139","LU0550127509.SGD","LU0979878070.USD","BK4605","LU0274383776.USD","DAMD","LU2458330169.SGD","LU2041044095.USD","BK4534","AMDL","LU2054465674.USD","LU2237957902.USD","LU0642271901.SGD","IE00BQXX3C00.GBP","LU1242518857.USD","AMDU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643061290","title":"Avalo Therapeutics amends executive employment deals, boosts change-in-control severance terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2643061290","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643061290?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:08","pubTimestamp":1781294913,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics amended employment agreements for CEO Garry A. Neil, CFO Christopher Sullivan, CMO Mittie Doyle, and CBO Taylor Boyd, effective June 12, 2026.Outside a change-in-control window, termination without cause or for good reason triggers 12 months’ base-salary severance, or 18 months for Neil.Within three months before through 12 months after a change in control, severance shifts to 1x base salary plus 1x target bonus, or 1.5x salary for Neil.Change-in-control terminations also provide full acceleration of time-based equity awards; vested options remain exercisable for up to 12 months for Neil, Sullivan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL9kqyyZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":0.0555},{"period":"3month","weight":0.3311},{"period":"6month","weight":0.2078},{"period":"1year","weight":1.3131},{"period":"ytd","weight":0.005}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.063135},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.010519},{"month":3,"riseRate":0.272727,"avgChangeRate":0.280205},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.088879},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.046144},{"month":6,"riseRate":0.727273,"avgChangeRate":0.024954},{"month":7,"riseRate":0.454545,"avgChangeRate":0.02164},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034606},{"month":9,"riseRate":0.6,"avgChangeRate":0.04604},{"month":10,"riseRate":0.6,"avgChangeRate":0.161359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.047903}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction